EGFR T790M/L858R-IN-6 is a small molecule inhibitor designed to target specific mutations in the epidermal growth factor receptor (EGFR), particularly the T790M and L858R mutations, which are commonly associated with non-small cell lung cancer (NSCLC). This compound functions by selectively inhibiting the activity of the mutated EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. The chemical structure of EGFR T790M/L858R-IN-6 typically includes functional groups that enhance its binding affinity and specificity for the mutated receptor. Its pharmacological profile suggests that it may exhibit improved efficacy compared to earlier generation EGFR inhibitors, particularly in patients who have developed resistance to first-line therapies. Additionally, the compound is likely to undergo extensive preclinical and clinical testing to evaluate its safety, efficacy, and pharmacokinetics. As with many targeted therapies, understanding its mechanism of action and potential side effects is crucial for optimizing treatment strategies in oncology.

EGFR T790M/L858R-IN-6

3032760-71-4: EGFR T790M/L858R-IN-6 is a small molecule inhibitor designed to target specific mutations in the epidermal growth factor receptor (EGFR), particularly the T790M and L858R mutations, which are commonly associated with non-small cell lung cancer (NSCLC). This compound functions by selectively inhibiting the activity of the mutated EGFR, thereby blocking downstream signaling pathways that promote tumor growth and survival. The chemical structure of EGFR T790M/L858R-IN-6 typically includes functional groups that enhance its binding affinity and specificity for the mutated receptor. Its pharmacological profile suggests that it may exhibit improved efficacy compared to earlier generation EGFR inhibitors, particularly in patients who have developed resistance to first-line therapies. Additionally, the compound is likely to undergo extensive preclinical and clinical testing to evaluate its safety, efficacy, and pharmacokinetics. As with many targeted therapies, understanding its mechanism of action and potential side effects is crucial for optimizing treatment strategies in oncology.

<p>EGFR T790M/L858R-IN-6 (compound 53), classified as a pyrimidine compound, serves as an effective inhibitor of EGFR T790M/L858R, demonstrating 90.88% inhibition of enzyme activity at a concentration of 0.05 μM [1].</p>

CAS 3032760-71-4

EGFR T790M/L858R-IN-6

EGFR T790M/L858R-IN-6

Ref: TM-T86347